Latest news and press releases about PMV Pharmaceuticals, Inc. (PMVP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state.
Price
| Price | $1.43 |
| Market Cap | $76M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.11 |
| EV / EBITDA | -0.74 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -78.11% |
| Return on Invested Capital | -111.08% |
| Return on Assets | -91.66% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACRV · ATYR · BMEA · CBUS · IMUX · LITS · RLMD
Explore sector: Healthcare · Biotechnology
More sections of PMVP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks